跳至主要內容
HER2+ Online Consensus
搜尋
Treatment Algorithm
HR+/HER2–: Endocrine Sensitive
HR+/HER2–: Endocrine Resistance
Radiological PD
HR+/HER2–: Endocrine Refractory
Treatment Algorithm
HR+/HER2–: Endocrine Sensitive
HR+/HER2–: Endocrine Resistance
Radiological PD
HR+/HER2–: Endocrine Refractory
Consensus Statements
Risk Evaluation and Biomarker Testing (I)
Risk Evaluation and Biomarker Testing (II)
Selection of First-Line Treatment (I)
Selection of First-Line Treatment (II)
Selection of Second-Line Treatment(I)
Selection of Second-Line Treatment (II)
Non-Endocrine Based Approaches(I)
Non-Endocrine Based Approaches (II)
Consensus Statements
Risk Evaluation and Biomarker Testing (I)
Risk Evaluation and Biomarker Testing (II)
Selection of First-Line Treatment (I)
Selection of First-Line Treatment (II)
Selection of Second-Line Treatment(I)
Selection of Second-Line Treatment (II)
Non-Endocrine Based Approaches(I)
Non-Endocrine Based Approaches (II)
Treatment Algorithm
HER2+ eBC
HER2+ mBC
First-line mBC
Brain Metastasis
Treatment Algorithm
HER2+ eBC
HER2+ mBC
First-line mBC
Brain Metastasis
Consensus Statements
HER2+ eBC: Neoadjuvant/Adjuvant Therapy
Clinical Benefit and Risk Evaluation of Neoadjuvant Treatment
Recommendation of Regimens of Adjuvant/Neoadjuvant Treatment
Recommendation of Systemic Adjuvant Treatment According to Pathological Response and Baseline Risk stratification after Neoadjuvant treatment
HER2+ eBC: Extended Adjuvant Therapy
HER2+ eBC: ILD Surveillance
HER2+ mBC: First-Line Therapy
De Novo or TFI ≥12m
6m < TFI < 12m
TFI ≤ 6m (no T-DM1)
TFI ≤ 6m (T-DM1)
HER2+ mBC: First-Line Maintenance
HER2+ mBC: Brain Metastasis
Consensus Statements
HER2+ eBC: Neoadjuvant/Adjuvant Therapy
Clinical Benefit and Risk Evaluation of Neoadjuvant Treatment
Recommendation of Regimens of Adjuvant/Neoadjuvant Treatment
Recommendation of Systemic Adjuvant Treatment According to Pathological Response and Baseline Risk stratification after Neoadjuvant treatment
HER2+ eBC: Extended Adjuvant Therapy
HER2+ eBC: ILD Surveillance
HER2+ mBC: First-Line Therapy
De Novo or TFI ≥12m
6m < TFI < 12m
TFI ≤ 6m (no T-DM1)
TFI ≤ 6m (T-DM1)
HER2+ mBC: First-Line Maintenance
HER2+ mBC: Brain Metastasis
點我看HR+/HER2- mBC Online Consensus
First-line mBC
(2026 UPDATE)
